Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Little River company creates EPA approved disinfectant solution for hospitals
https://www.wmbfnews.com/2020/04/15/little-river-company-creates-epa-approved-disinfectant-solution-hospitals/
HORRY COUNTY, S.C. (WMBF) - A small business in Horry County is helping hospitals across the country in the fight against the coronavirus.
The product is called Hydrolyte. The bottle claims it kills up to 99.9% of bacteria in two minutes.
Gary Grieco, the company's CEO, said so far they've shipped out thousands of gallons to hospitals in North Carolina, Nevada and ten hospitals in New York, which is the epicenter of the virus.
“We have to become proactive in this country and always be defending ourselves against viruses and bacteria the way we are against terrorism,” Grieco said. “They’re always going to be there, it’s just going to make it a lot safer for people to walk around and interact.”
The disinfectant is made with salt, water and electricity.
Stuart Emmons, vice president of engineering and production, said the product is hypochlorous acid-based, which is what the human body naturally produces to fight off infections.
It’s also listed as EPA level four toxicity. This means the product isn’t harmful to those who use it and doesn’t require personal protective equipment.
"The hydrochlorous acid being much more effective at a much lower concentration allows people to spray this when there’s other people in the room without there being a lot of fumes that may be overwhelming to patients and visitors that might be around,” Emmons said.
The demand for the product increased so much they had to hire more people to help.
Cindi Schoeber said she was recently hired after being laid off from a restaurant impacted by COVID-19.
“I have a nurse in south Jersey and the hospital is overrun,” Schoeber said. “They shipped product to her and I shipped product to my other children in south Jersey."
Grieco said they’re currently able to produce around 10,000 gallons of fluid per day.
If you’re a first responder or healthcare worker, the company offers to disinfect your car and give you a bottle for free.
Hypochlorous Acid Market Analysis 2020 Growth Challenges, Opportunities and Forthcoming Developments
Published: March 2, 2020 at 1:04 a.m. ET
Mar 02, 2020 (The Expresswire) -- Global Hypochlorous Acid Market is to be expected to observer an impressive CAGR during the forecast period. From an insight perspective, the Hypochlorous Acid trend market report focuses on various levels of analyses- growth trends, numerous stakeholders like investors, CEOs, traders, suppliers, analysis & media, international Manager, Director, President, SWOT analysis and Threat to the organization and others.
The Global “Hypochlorous Acid“Market Report 2020report supplies thorough estimation to improvement a complete information of the global Hypochlorous Acid market today and its industrial outlook based completely on current and purpose marketplace. This report focuses on Professional Global Hypochlorous Acid Market Trend 2020-2024 volume and value at global level, regional level and company level.
Hypochlorous acid is a weak acid that can only exist in solution, because it is highly unstable when isolated in a pure form. There are a number of uses for this chemical, most of which take advantage of its strong oxidating properties, which allow it to be used as a bleach and disinfectant, among many other things. Many manufacturers produce this acid for sale to both industrial users and ordinary consumers, and many stores carry it, typically in the household cleaning section. Though it can be safely used when diluted, it can be very dangerous when concentrated.,
market for Hypochlorous Acid is expected to grow at a CAGR of roughly 0.1% over the next five years, will reach 1510 million USD in 2023, from 1500 million USD in 2017, according to a new (Global) study.,
Those growth projections was before the Pandemic blew up.
Hypochlorous Acid Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026
Published Date: July 2019
https://www.gminsights.com/industry-analysis/hypochlorous-acid-market
Hypochlorous Acid Market size is expected to witness significant growth over the projected timespan owing to rising demand for sodium and calcium hypochlorite from application industries. Increasing prevalence of wound disease such as diabetic foot ulcers, pressure and venous ulcers is projected to have positive impact on the market growth.
Hypochlorous acid is widely used in wound healing solutions as it helps in dissolving biofilms that are formed on chronic wounds that prevent healing and increase the risk of blood toxicity levels. Global wound healing market was over USD 30 billion in 2018 owing to rising acute and chronic wounds, low platelet counts, and hemophilia which results in slows down the rate of wound healing process. Hypochlorous acid aids faster healing as its application results in nearly eight hours of keratinocyte cell line mitigation in comparison with other wound healing products such as iodine, may trigger the hypochlorous acid market demand.
Increasing consumer awareness regarding the importance of clean water and stringent government regulations to safeguard the supply of water may foster hypochlorous acid market share. In Belgium, wastewater treatment market was over USD 50,0000 in 2018 and expected to witness significant growth owing to rapid urbanization and increasing population. Hypochlorous acid possesses stable disinfectant properties and is added to public water supplies to treat disease causing pathogens such as protozoans, bacteria, and viruses that commonly palpate in water supply reservoirs and on the walls of storage tanks. It is one of the most effective biocides, shares weak acid bond and is produced in human body to fight infection and kill invasive organisms which makes it safe for human and animal consumption thereby having positive impact on hypochlorous acid market growth.
Hypochlorous acid possesses infection fighting compounds found naturally in the body and helps in reducing acne inflammation and scars by protecting against environmental aggressors such as dirt and pollution. Increase in prevalence of skin problems such as acne, scars and cold sores owing to rise in air pollution levels and changing dietary patterns may boost market share. The properties of hypochlorous acid such as its antiviral and antimicrobial nature helps in healing acne scars by triggering epithelial knitting and oxygenation levels under skin layer which may accelerate hypochlorous acid market share.
Hypochlorous acid is widely used in manufacturing deodorant as it is produced by the electrolysis of salt and water without the interference of chemical materials that cause symptoms of redness and chaffing. Increasing disposable income, rise in consumer awareness related to personal hygiene along with the adverse effects of calcium salts in deodorants may increase hypochlorous acid market penetration in personal care products thereby boosting market growth. In UK, over 17 million people used aerosol spray deodorants in 2017 owing to rising consumer inclination to avoid body odor. It is effective against a wide range of viruses and bacteria that cause body odor, can be applied to different skin types, finds computability with aerosol medium, and helps in maintaining moisture levels thus preventing flaking which may foster market share.
North America hypochlorous acid market size led by the U.S. and Canada should witness a significant growth during forecasted period owing to increasing demand for wound healing solutions. In U.S over 1.25 million people were diagnosed with diabetes in 2016 which has increased the prevalence of chronic wounds among geriatric population. Diabetes decreases the wound healing rate as high levels of insulin affects the nerves which leads to poor circulation resulting in delayed skin repair. Hypochlorous acid helps in triggering the production of new skin cells and reduces infection by preventing pus formation and contamination by bacteria which foster market share.
Europe driven by UK, France, Italy, and Germany hypochlorous acid market demand may witness moderate growth during forecasted period. Hypochlorous acid is easy to store, cost efficient, and possess nontoxic nature which makes it attractive to use in restaurant industry as a sanitizing agent which may trigger product demand. Hypochlorous acid is widely used in manufacturing sanitizers for food & beverage industry for sanitizing food preparations areas, counter tops, tables, and grills to prevent contamination from meat, seafood, and other organic produce which may accelerate market share. In UK, average weekly spending on restaurants and hotels between the age group of 30 to 49 was over USD 75 in 2018. Changing consumer perceptions towards fine dining, stringent European Union regulations related to food safety and busy schedules may stimulate hypochlorous acid market from their applications in restaurants, hotels and café’s.
Asia Pacific hypochlorous acid market demand led by Japan, China, and India may see significant growth. Hypochlorous acid is compatible with organic & inorganic chemicals, shows microbicidal properties and is highly stable when applied to counter bacteria, viruses, and fungi which helps in reducing inflation. Increase in prevalence of skin problems such as acne, wrinkles, cold scores, and scars owing to sedentary lifestyles, inclination towards western foods with high fat content, and rising pollution levels may trigger the market demand. In South Korea, over 40% of males were diagnosed with acne in 2018 owing to increase in bacterial and microbial acne breakouts may have positive impact on market growth.
Global hypochlorous acid market share is fragmented as market consist of several small, medium and major market players. Companies such as Kemin Industries, BASF, Lenntech, Arkema S.A., Nouryon, Lonza, Kuehne Company, Tosoh Corporation, Aditya Birla Chemicals, Surpass Chemical Company, Ultrapure HOCL, AGC Chemicals, Westlake Chemical Corporation, Tianjin Ruifuxin Chemical, and Westlake Chemical Corporation are key players in the market.
Extra Extra Read All About it:
PCTL is cash flow positive and there is no DOUBT ABOUT IT!!!
COMPETITION is in PCTL past, present and future
Just focusing on our flagship product, The Annihilyzer® Infection Control System, how does PCTL compare to other companies for whole room cleaning only?
Our competitors include companies that sell whole room Infection Control Systems.
There are many different products in use to disinfect hospital rooms such as UV light, hydrogen peroxide vapor, Aerosolized hydrogen peroxide, Ozone gas, cluster ion air, Mercury UV-C light and hypochlorus acid (PCTL).
Ultraviolet light breaches the cell walls of viruses, bacteria and spores to deactivate their DNA and kill them in the air and on surfaces. Two types of devices use UV-C for germicidal irradiation: continuous light systems with 1- to 2-hour cycles and xenon-based pulsed light systems with 5- to 10-minute cycles. Both require direct illumination to treat targeted surfaces.
Hydrogen peroxide vapor systems deliver a heat-generated odorless vapor, which uses oxidative processes to kill microorganisms. When the systems are in use, a room’s doors, ducts and ventilation ports must be sealed.
Aerosolized hydrogen peroxide is uniformly sprayed with a pressure-generated aerosol, which delivers a residue-free mist that is typically made up of 5% to 6% hydrogen peroxide and a very small percentage of silver.
Ozone gas has been used in conjunction with high-powered air filtration and UV light to rid surfaces and air of microbe colonization.
Cluster ion air purifiers actively seek out pathogens via electromagnetic charge. On contact, their stored energy is unleashed through the pores of cell walls, destroying bacteria from the inside out.
Mercury UV-C light devices use low-pressure mercury gas bulbs that primarily emit a strong, narrow band of the UV-C spectrum. These devices use a dose targeted for specific types of bacteria on surfaces.
Hypochlorus acid use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched in the industry to ensure proper and complete application.
Base your whole-room disinfection choice on how a system works in practice and the value you place on reducing the risk of healthcare-acquired infections (HAIs). Each system’s disinfection agent and its mechanism of action require specific preparations to achieve optimal results. A room’s size and shape, the layout of its equipment and fixtures, and the reflectivity of its surfaces can all impact effectiveness.
UVC light systems need clear lines of sight to treat surfaces; if the light doesn’t hit a particular spot, it doesn’t disinfect it. That means you might have to reposition the unit between multiple cycles and move equipment around the room to ensure all surfaces are treated.
Systems that use hydrogen peroxide and other combinations of mists and vapors are less dependent on line of sight. They are, however, potentially more labor intensive because you have to cover air vents and seal OR doors before activating the devices. Time also is needed for chemicals to sufficiently dissipate before you can re-enter a disinfected room.
Hypochlorous acid (HOCl) is the perfect weapon to fight germs. It hits hard against pathogens like Methicillin-Resistant Staphylococcus Aureus and Pseudomonas Aeroginosa. Yet this powerful weapon is 100 percent safe for humans, chemical free, non-toxic and all-natural.
What makes The Annihilyzer Infection Control System better than others systems?
The Annihilyzer® uses patented and patent pending RFID/NFC technology to manage the product expiration and usage information.
When a container is filled, an expiration date is assigned to the container and imprinted on the RFID tag embedded in the bottle’s label.
The system keeps track of who filled the container and when. If an expired container is presented at the Kiosk, the PCT Annihilyzer® alerts the user to empty and refill it, ensuring the quality of the product contents.
The mobile PCT Annihilyzer Electrostatic Application System (AEAS) which is housed in a rolling cart is used quickly decontaminate and disinfect large areas, difficult to reach spaces and high-touch areas that require frequent treatment.
The AEAS electrostatic sprayer head produces positively-charged droplets of the Hydrolyte® disinfectant solution using a unique embedded-induction electrode. The electrostatic charge on every droplet pulls them towards the targeted surfaces at 75 times the force of gravity. This means droplets will even move upwards, against gravity, to coat hidden surfaces and wrap around objects, resulting in complete, even coverage of the target surfaces.
Independent tests demonstrate up to 50 percent better coverage than that achieved using non-electrostatic fogger or sprayer systems.
GREEN SEAL™ CERTIFIED 110V Units can plug right into a regular outlet snd generate full-strength hypochlorus (disinfectant) and sodium hydroxide (cleaner) on site - which can be easily dispensed on-demand. solution for our clients and our communities.
Disinfecting solutions that offer an elevated level of safety for patients, healthcare professionals, and support staff to be around; while at the same time providing an effective weapon in the fight against infection.”
We certainly have a hell of a Flagship product. Now that I gave you some candy, I'm going to throw some rocks your way.
Even though we have a very competitive product and possibly the best on the market here are the challenges we have to overcome to beat the competitors.
Getting in the hospital doors had been difficult and tedious. We still face this challenge as many hospitals and healthcare facilities have long standing relationships with some of the competitors and people don’t like change.
Our smallness limits our ability to do normal business activities on a scale that a bigger and more properly funded company does such as advertising, large sales forces and financing. We may have the best solution in town however if hospitals aren’t hearing about it how can they get it. Also companies with a large salesforce are more well equipped to sell more products not because it is better but because of contact with potential buyers and to some extent salesmanship and long standing relationships. You all heard the story about Chuck the “salesman” he could sell you your shirt off your back.
“The top salespeople are usually the ones with the most activity; it doesn’t guarantee you will close more deals, but if you have no activity, you won’t be closing any deals.” – Colleen Honan, Chief Sales Officer, Brainshark
Many facilities have a contract in place for Infection Control Systems and until those contracts expire they are unavailable.
Time stops for no one. This can work for us or against us. There is a greater demand for Infection Control Systems that the market can provide. In the short term we may lose market share as we may be limited by the amount of systems we can push out but as time progresses we should be able to increase production.
What does all this mean?
PCTL has a great and competitive product however they face challenges that they should overcome as time progresses. As more and more of their systems hit the marketplace word will get out from satisfied customers.
The arrival of Covid 19 has forced healthcare facilities to rethink what is the best way to keep their environments safe. The bottom line is PCTL has possibly the best and definitely the most versatile Infection Control Systems the marketplace has ever seen.
Why has PCTL expanded so much in New York?
We have a distributor there getting the word out.
Hospitals with the systems may have shared their experiences with sister hospitals.
If we can duplicate this plan in other big market areas we may reach similar results.
That sums it up and the focus was just hospitals and PCTL’s flagship product.
What about all the other products in PCTL’s arsenal?
Bring on the competition we are locked and loaded.
PCTL has moved from toxic financing to a company on a cash flow basis to cover burn-rate in just 6 Months.
“But life inevitably throws us curve balls, unexpected circumstances that remind us to expect the unexpected. I've come to understand these curve balls are the beautiful unfolding of both karma and current.” Carre Otis
From the 3rd quarter 10Q:
Liquidity and Capital Resources:
A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate generating sufficient positive internal operating cash flow until such time as we can deliver our products to market and generate substantial revenues, which may take the next full year to fully realize, if ever. In the event we cannot obtain the necessary capital to pursue our strategic plan, we may have to significantly curtail our operations. This would materially impact our ability to continue operations.
From the Press release dated April 21, 2020:
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow is the being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco.
“So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
Why the dramatic change?
PCTL core business operations have exploded due to demand for their products.
From the March 25, 2020 and April 21, 2020 Press Releases:
“The demand for our products has been nothing short of explosive,” explains CEO Gary Grieco. “Due to this high demand, we are shifting our focus, in the short term, towards fluid production, sales, and distribution.”
The company has shifted its focus towards fulfilling an increasing number of fluid orders. To meet this growing demand, PCTL is expanding its production capacity and will double their current fluid production output within the next week to ten days.
Jody Read, COO stated: “We are still continuing to see significant interest in the facility-based Annihilyzer® Infection Control System. However, we are not able to coordinate installations due to travel restrictions and availability of hospital staff to implement the systems. We are continuing to build systems and at the same time utilize our current South Carolina facility’s capabilities with large volume systems to produce mass quantities of disinfectant for distributors and hospitals.
If one of our distributors did at least $700,000 in sales in March, I cannot fathom what the "PCTL" aka "the Mother Ship" sales were.
Also this distributor stated the following:
We have to take care of our existing customers, and their medical side that are front line and we’re also working with some new ones, but we definitely can’t meet all the demand. The largest companies out there can’t come close to meeting all their demands. So, obviously a young, family-owned business like ours, we’re doing the best we can.
So What does this mean?
PCTL still has to clean up their debt.
PCTL may need financing for growth and expansion if their cash flow isn’t enough to cover these requirements.
What is PCTL’s future?
“Optimism is a strategy for making a better future. Because unless you believe that the future can be better, you are unlikely to step up and take responsibility for making it so.”
? Noam Chomsky
The Annihilyzer® Infection Control System remains the company’s flagship product and continues to garner intense interest from prospective hospitals and healthcare facilities.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
“Growth has been tremendous,” says CFO Marion Sofield, adding that the company is expecting to report record sales and revenues in Q1 2020.
“We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
It is very promising and could really explode if they land BIG business from the UK. Testing is underway according to the April 16, and 21, 2020 Press Releases:
The first PCT system has now been installed in a large NHS hospital in the north of England. This system is expected to enter clinical service early in May once the final series of biological tests of the PCT hospital disinfectant solution have been completed. Results of these tests have so far demonstrated that the PCT disinfectant has met or exceeded its ability to kill the range of pathogens previously achieved during EPA tests in the United States.
Jolly then commented on the Company’s latest press release detailing a distribution agreement with the UK NHS company. Grieco shared that the agreement will likely begin with five systems starting in July and will later expand to fulfill the needs of their healthcare system.
In 2018, Pure & Clean’s annual revenue was $350,000. Amid the COVID-19 pandemic, you say sales of your natural disinfectants have surged in the last month. What were March sales?
It was equal to [total] 2019 sales, which were more than double 2018 sales. It’s kind of an interesting feeling in this time of so many people hurting with small businesses and even large businesses. We’re a great solution for what’s going on, for protecting yourself and then also for disinfecting surfaces and areas. Scaling to that is obviously something that you can’t prepare for and we obviously weren’t ready for."
I believe the reference is clearly to the annual revenue of $350,000 because it intentionally included the word total.
Probably much of that annual revenue came from a big part of their business which is outsourced:
We’ve hired more people. We’ve outsourced a big part of our business, which is our optometry and ophthalmology, vision, side of our company. That has been a huge part of our growth, adding hundreds of optometry clinics around the country. It also takes time and energy and effort to get your fulfillment moved over to another company and get them educated on how you do things and what you expect and what your customers expect. Every day was new opportunities for us, but also new difficulties in figuring out how we can take care of front-line people that are fighting this, from firefighters and emergency personnel to hospitals and clinics, to just essential businesses that need to be open to keep taking care of their customers.
The article references natural disinfectants (HOCI being one).
The article talks about scaling.
The article talks about local demand and mentions working with some of the largest hospitals in the country.
Where are you seeing the demand locally for these products?
It’s from individuals just wanting to get something to protect themselves. A lot of those individuals are people who are working on the front lines of the health care systems in town. A lot of people are in long-term care facilities that are taking care of a high-risk population. Honestly, our business right now, a lot of it is from all over the nation. Large companies reaching out that need to protect their employees. We work with some of the largest hospital systems in the nation.
The article talks about inability to meet demands.
We were supposed to be at the NCAA wrestling championships in March in Minnesota. I was supposed to go from there to Vision Expo East in New York and that was canceled. We were supposed to be at the Olympics this summer with our products. Team USA had already purchased product to be shipped out to Japan for the Olympics. Our sports line has pretty much been shut down, and our medical and consumer side is just crazy. We have to take care of our existing customers, and their medical side that are front line and we’re also working with some new ones, but we definitely can’t meet all the demand. The largest companies out there can’t come close to meeting all their demands. So, obviously a young, family-owned business like ours, we’re doing the best we can.
This article is all about HOCI and $700,000 Pure&Clean sold in March.
Their biggest HOCI item on their website is a 265 gallon tote.
It wouldn’t take too many of those to get to $700,000.
In 2018, Pure & Clean’s annual revenue was $350,000. Amid the COVID-19 pandemic, you say sales of your natural disinfectants have surged in the last month. What were March sales?
It was equal to [total] 2019 sales, which were more than double 2018 sales. It’s kind of an interesting feeling in this time of so many people hurting with small businesses and even large businesses. We’re a great solution for what’s going on, for protecting yourself and then also for disinfecting surfaces and areas. Scaling to that is obviously something that you can’t prepare for and we obviously weren’t ready for.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155697883
If one of our distributors did at least $700,000 in sales of "pool water" in March 2020, I cannot fathom what the "PCTL" aka "the Mother Ship" sales were.
Here is the link the info came from:
https://www.optometrytimes.com/blog/hypochlorous-acid-harnessing-natures-germ-killer
More info:
Our line of industry-specific electrochemically engineered solutions works to replicate the HOCl produced inside the human body. Setting the Gold Standard for efficacy: MyOxy is proven pure and stable, laboratory tested, and yields excellent results. Through MyOxy’s achievements, for the first time in 130 years, HOCl can be produced without ill-defined or unknown contaminants, offering reliability even after storage for unprecedented periods of time. Our formulations never contain additives, buffers, or preservatives, and remain free of alcohol, oil, parabens, sulphates, or added fragrance — The power is in our purity.
https://www.bulkhocl.com/
Why isn’t Hypochlorous Acid everywhere?
The overwhelming impediment to its widespread use has been a lack of shelf stability. HOCl is the most reactive ROS (Reactive Oxygen Species). This means it reacts very easily and will quickly turn back into saltwater. HOCl solutions have been used for over 100 years. in the early 1900s during the World Wars, HOCl solutions were used for disinfecting medical equipment and dressing wounds. However, until recently, HOCl solutions would only remain stable for about 90 minutes before turning back into saltwater.
What has changed?
HOCl is now manufactured in a way that allows the solution to be stable for much longer than previously available. This has allowed for the product to be carefully bottled and made available across the world. Although producing HOCl solutions is not challenging, stabilizing the solution is very difficult. In fact, at MyOxy our quality ingredients and unique process produce an unmatched product. This is proven by our HOCl industry-best 24-month cleared shelf life on all of our products. Furthermore, we do not add unnecessary ingredients to stabilize or preserve our product stability.
https://www.bulkhocl.com/what-is-hoci
How is HOCl made?
Michael Faraday founded the laws of electrolysis and it became commercially available in the 1870s.
Generating HOCl from the electro-chemical activation (ECA) of salt water was developed in the 1970s.
Early ECA technology used membranes to force saltwater into two solutions of HOCl and NaOH.
In the 1980s, single stream systems were developed that produced one solution of HOCl without byproduct.
In recent, single stream systems have been innovated to last longer and generate more stable solutions.
https://www.hypochlorousacid.com/
Why do you assume that his 2018 and 2019 is just HOCI fluids. They have many other products that they sell. I'm assuming that the $700,000 in sales was for HOCI in March 2020 and I'm assuming that PCTL sold much, much more than that. Heck PCTL had to get out an order of 10,000 gallons and fill another for that amount right away. PCTL had to reorganize their operations to keep up with demand. Also PCTL had record sales in Q1.
I'm not concern with what PCT derived from selling fluid in 2019 or 2020.
The man said he had sales for one month, March 2020 that was equal to the total sales from one year which is $700,000. He didnot bring PCT into the equation so why are you.
This happen at the same time PCT sales were exploding and the information in the interview clearly points to what he was selling.
This information just magnifies the tremendous demand for HOCI.
The article is about HOCI and the focus of the conversation is about the pandemic and how to help fight it. Also what other items could they possibly be selling with everything shut down. This lines up with what was going on at PCTL location in Little River.
In 2018, Pure & Clean’s annual revenue was $350,000. Amid the COVID-19 pandemic, you say sales of your natural disinfectants have surged in the last month. What were March sales?
It was equal to [total] 2019 sales, which were more than double 2018 sales. It’s kind of an interesting feeling in this time of so many people hurting with small businesses and even large businesses. We’re a great solution for what’s going on, for protecting yourself and then also for disinfecting surfaces and areas. Scaling to that is obviously something that you can’t prepare for and we obviously weren’t ready for.
We’ve hired more people. We’ve outsourced a big part of our business, which is our optometry and ophthalmology, vision, side of our company. That has been a huge part of our growth, adding hundreds of optometry clinics around the country. It also takes time and energy and effort to get your fulfillment moved over to another company and get them educated on how you do things and what you expect and what your customers expect. Every day was new opportunities for us, but also new difficulties in figuring out how we can take care of front-line people that are fighting this, from firefighters and emergency personnel to hospitals and clinics, to just essential businesses that need to be open to keep taking care of their customers.
Where are you seeing the demand locally for these products?
It’s from individuals just wanting to get something to protect themselves. A lot of those individuals are people who are working on the front lines of the health care systems in town. A lot of people are in long-term care facilities that are taking care of a high-risk population. Honestly, our business right now, a lot of it is from all over the nation. Large companies reaching out that need to protect their employees. We work with some of the largest hospital systems in the nation.
Other sources has already shown that the Podcasts and PRs are factual and accurate. We just don't know PCTL's numbers:
“Facts are stubborn things; and whatever may be our wishes, our inclinations, or the dictates of our passion, they cannot alter the state of facts and evidence.”
? John Adams,
If one of our distributors did at least $700,000 in sales in March, I cannot fathom what the "PCTL" aka "the Mother Ship" sales were.
https://sbj.net/stories/a-conversation-with-trent-freeman,68592?fbclid=IwAR2azCc3_Q1ijaqbX1wcAcJkDydV4xJZF2CVVX1QemQyBkOqK5Lrd_Ksszk
IMS uses hyphochlorous acid generated from the Annihilyzer system. Natures safe and effective disinfectant.
https://www.linkedin.com/feed/update/urn:li:activity:6651456530740768768/?fbclid=IwAR21t1nEXq5ljCjvSoE6iIuk8fXzc4Dvgknr6xqHhuc-U3kN5X44srPfMGk
Disinfecting surfaces to hospital level should be priority for all as awareness of viruses becomes more prevalent around the world. Leading the charge in many NY hospital systems is the #Annihilyzer System. #PreventionOverPanic #awareness @EPA @CDCgov @CDCGlobal @realDonaldTrump https://t.co/F5MdOTTjeA
https://www.twipu.com/Wophos/tweet/1241444403727814657
$PCTL Doing BIG things in #hospitals in coordination with Ace Janitorial in Brooklyn (https://t.co/IshedzLKju) & the #Annihilyzer Infection Control System. Demand is at an all time high! https://t.co/djLhkijOfj #InfectionControl #infectionprevention #COVID?19 #COVID19 https://t.co/Xg6DOaCaFq
https://www.twipu.com/Wophos/tweet/1242137087857524736
Thanks to beer$$money post 105547!!! A must Sticky!!!
If one of our distributors did at least $700,000 in sales in March, I cannot fathom what the "PCTL" aka "the Mother Ship" sales were.
We do know they were record breaking:
“Growth been tremendous,” says CFO Marion Sofield, adding that the company is expecting to report record sales and revenues in Q1 2020.
I really can't imagine what Q2 2020 sales will look like other than to say they are going to be unbelievably huge.
Pure & Clean As a distributor of PCTL EPA Reg. No. 92108-1,
the product pure&clean™ (EPA Reg. No. 92108-1-88098) is included on the list of products approved by the US EPA on the List-N.
A Conversation With ... Trent Freeman CEO, Pure & Clean LLC
April 20, 2020
In 2018, Pure & Clean’s annual revenue was $350,000. Amid the COVID-19 pandemic, you say sales of your natural disinfectants have surged in the last month. What were March sales?
It was equal to [total] 2019 sales, which were more than double 2018 sales. It’s kind of an interesting feeling in this time of so many people hurting with small businesses and even large businesses. We’re a great solution for what’s going on, for protecting yourself and then also for disinfecting surfaces and areas. Scaling to that is obviously something that you can’t prepare for and we obviously weren’t ready for.
Have you hired more employees? Increased production hours?
We’ve hired more people. We’ve outsourced a big part of our business, which is our optometry and ophthalmology, vision, side of our company. That has been a huge part of our growth, adding hundreds of optometry clinics around the country. It also takes time and energy and effort to get your fulfillment moved over to another company and get them educated on how you do things and what you expect and what your customers expect. Every day was new opportunities for us, but also new difficulties in figuring out how we can take care of front-line people that are fighting this, from firefighters and emergency personnel to hospitals and clinics, to just essential businesses that need to be open to keep taking care of their customers.
Why did you start Pure & Clean in 2014?
We really started off trying to just take care of athletes and protect them from skin infections – some things that they could get that would affect them for the rest of their life. From there, we grew and developed. We had two divisions. One was focused on sports and protecting our athletes, and the other side was focused on the medical side and wound care and hospital business. We have hospital-grade disinfectants, and we have over-the-counter and Rx solutions for wound care. All kinds of things to help people heal and recover from a trauma or a post-surgical wound or infection.
Where are you seeing the demand locally for these products?
It’s from individuals just wanting to get something to protect themselves. A lot of those individuals are people who are working on the front lines of the health care systems in town. A lot of people are in long-term care facilities that are taking care of a high-risk population. Honestly, our business right now, a lot of it is from all over the nation. Large companies reaching out that need to protect their employees. We work with some of the largest hospital systems in the nation.
Have your costs or prices changed during this time of high demand?
We definitely have had a lot of increase in our costs as far as our hard costs to us with more employees, expanding our facilities and outsourcing our fulfillment center. But we haven’t increased any costs to our end users or even our distributors. That’s the last thing we want to do when people are struggling right now is to price gouge or increase our cost to them.
How have the other parts of your business changed in the past couple months?
We were supposed to be at the NCAA wrestling championships in March in Minnesota. I was supposed to go from there to Vision Expo East in New York and that was canceled. We were supposed to be at the Olympics this summer with our products. Team USA had already purchased product to be shipped out to Japan for the Olympics. Our sports line has pretty much been shut down, and our medical and consumer side is just crazy. We have to take care of our existing customers, and their medical side that are front line and we’re also working with some new ones, but we definitely can’t meet all the demand. The largest companies out there can’t come close to meeting all their demands. So, obviously a young, family-owned business like ours, we’re doing the best we can.
Trent Freeman can be reached at tfreeman@pureandclean.us.
https://sbj.net/stories/a-conversation-with-trent-freeman,68592?fbclid=IwAR2azCc3_Q1ijaqbX1wcAcJkDydV4xJZF2CVVX1QemQyBkOqK5Lrd_Ksszk
PCTL have free available cash flow.
PCTL has moved from toxic financing to a company on a cash flow basis to cover burn-rate in just 6 Months.
Our goals can only be reached through a vehicle of a plan, in which we must fervently believe, and upon which we must vigorously act. There is no other route to success. -Pablo Picasso
From the 3rd quarter 10Q:
Liquidity and Capital Resources:
A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate generating sufficient positive internal operating cash flow until such time as we can deliver our products to market and generate substantial revenues, which may take the next full year to fully realize, if ever. In the event we cannot obtain the necessary capital to pursue our strategic plan, we may have to significantly curtail our operations. This would materially impact our ability to continue operations.
From the Press release dated April 21, 2020:
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow is the being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco.
“So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
Why the dramatic change?
PCTL core business operations have exploded due to demand for their products.
From the March 25, 2020 and April 21, 2020 Press Releases:
“The demand for our products has been nothing short of explosive,” explains CEO Gary Grieco. “Due to this high demand, we are shifting our focus, in the short term, towards fluid production, sales, and distribution.”
The company has shifted its focus towards fulfilling an increasing number of fluid orders. To meet this growing demand, PCTL is expanding its production capacity and will double their current fluid production output within the next week to ten days.
Jody Read, COO stated: “We are still continuing to see significant interest in the facility-based Annihilyzer® Infection Control System. However, we are not able to coordinate installations due to travel restrictions and availability of hospital staff to implement the systems. We are continuing to build systems and at the same time utilize our current South Carolina facility’s capabilities with large volume systems to produce mass quantities of disinfectant for distributors and hospitals.
So What does this mean?
PCTL still has to clean up their debt.
PCTL may need financing for growth and expansion if their cash flow isn’t enough to cover these requirements.
What is PCTL’s future?
“Optimism is a strategy for making a better future. Because unless you believe that the future can be better, you are unlikely to step up and take responsibility for making it so.”
? Noam Chomsky
The Annihilyzer® Infection Control System remains the company’s flagship product and continues to garner intense interest from prospective hospitals and healthcare facilities.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
“Growth has been tremendous,” says CFO Marion Sofield, adding that the company is expecting to report record sales and revenues in Q1 2020.
“We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
It is very promising and could really explode if they land BIG business from the UK. Testing is underway according to the April 16, and 21, 2020 Press Releases:
The first PCT system has now been installed in a large NHS hospital in the north of England. This system is expected to enter clinical service early in May once the final series of biological tests of the PCT hospital disinfectant solution have been completed. Results of these tests have so far demonstrated that the PCT disinfectant has met or exceeded its ability to kill the range of pathogens previously achieved during EPA tests in the United States.
Jolly then commented on the Company’s latest press release detailing a distribution agreement with the UK NHS company. Grieco shared that the agreement will likely begin with five systems starting in July and will later expand to fulfill the needs of their healthcare system.
PCTL has moved from toxic financing to a company on a cash flow basis to cover burn-rate in just 6 Months.
“But life inevitably throws us curve balls, unexpected circumstances that remind us to expect the unexpected. I've come to understand these curve balls are the beautiful unfolding of both karma and current.” Carre Otis
From the 3rd quarter 10Q:
Liquidity and Capital Resources:
A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate generating sufficient positive internal operating cash flow until such time as we can deliver our products to market and generate substantial revenues, which may take the next full year to fully realize, if ever. In the event we cannot obtain the necessary capital to pursue our strategic plan, we may have to significantly curtail our operations. This would materially impact our ability to continue operations.
From the Press release dated April 21, 2020:
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow is the being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco.
“So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
Why the dramatic change?
PCTL core business operations have exploded due to demand for their products.
From the March 25, 2020 and April 21, 2020 Press Releases:
“The demand for our products has been nothing short of explosive,” explains CEO Gary Grieco. “Due to this high demand, we are shifting our focus, in the short term, towards fluid production, sales, and distribution.”
The company has shifted its focus towards fulfilling an increasing number of fluid orders. To meet this growing demand, PCTL is expanding its production capacity and will double their current fluid production output within the next week to ten days.
Jody Read, COO stated: “We are still continuing to see significant interest in the facility-based Annihilyzer® Infection Control System. However, we are not able to coordinate installations due to travel restrictions and availability of hospital staff to implement the systems. We are continuing to build systems and at the same time utilize our current South Carolina facility’s capabilities with large volume systems to produce mass quantities of disinfectant for distributors and hospitals.
So What does this mean?
PCTL still has to clean up their debt.
PCTL may need financing for growth and expansion if their cash flow isn’t enough to cover these requirements.
What is PCTL’s future?
“Optimism is a strategy for making a better future. Because unless you believe that the future can be better, you are unlikely to step up and take responsibility for making it so.”
? Noam Chomsky
The Annihilyzer® Infection Control System remains the company’s flagship product and continues to garner intense interest from prospective hospitals and healthcare facilities.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
“Growth has been tremendous,” says CFO Marion Sofield, adding that the company is expecting to report record sales and revenues in Q1 2020.
“We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
It is very promising and could really explode if they land BIG business from the UK. Testing is underway according to the April 16, and 21, 2020 Press Releases:
The first PCT system has now been installed in a large NHS hospital in the north of England. This system is expected to enter clinical service early in May once the final series of biological tests of the PCT hospital disinfectant solution have been completed. Results of these tests have so far demonstrated that the PCT disinfectant has met or exceeded its ability to kill the range of pathogens previously achieved during EPA tests in the United States.
Jolly then commented on the Company’s latest press release detailing a distribution agreement with the UK NHS company. Grieco shared that the agreement will likely begin with five systems starting in July and will later expand to fulfill the needs of their healthcare system.
COMPETITION is in PCTL past, present and future
Just focusing on our flagship product, The Annihilyzer® Infection Control System, how does PCTL compare to other companies for whole room cleaning only?
Our competitors include companies that sell whole room Infection Control Systems.
There are many different products in use to disinfect hospital rooms such as UV light, hydrogen peroxide vapor, Aerosolized hydrogen peroxide, Ozone gas, cluster ion air, Mercury UV-C light and hypochlorus acid (PCTL).
Ultraviolet light breaches the cell walls of viruses, bacteria and spores to deactivate their DNA and kill them in the air and on surfaces. Two types of devices use UV-C for germicidal irradiation: continuous light systems with 1- to 2-hour cycles and xenon-based pulsed light systems with 5- to 10-minute cycles. Both require direct illumination to treat targeted surfaces.
Hydrogen peroxide vapor systems deliver a heat-generated odorless vapor, which uses oxidative processes to kill microorganisms. When the systems are in use, a room’s doors, ducts and ventilation ports must be sealed.
Aerosolized hydrogen peroxide is uniformly sprayed with a pressure-generated aerosol, which delivers a residue-free mist that is typically made up of 5% to 6% hydrogen peroxide and a very small percentage of silver.
Ozone gas has been used in conjunction with high-powered air filtration and UV light to rid surfaces and air of microbe colonization.
Cluster ion air purifiers actively seek out pathogens via electromagnetic charge. On contact, their stored energy is unleashed through the pores of cell walls, destroying bacteria from the inside out.
Mercury UV-C light devices use low-pressure mercury gas bulbs that primarily emit a strong, narrow band of the UV-C spectrum. These devices use a dose targeted for specific types of bacteria on surfaces.
Hypochlorus acid use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched in the industry to ensure proper and complete application.
Base your whole-room disinfection choice on how a system works in practice and the value you place on reducing the risk of healthcare-acquired infections (HAIs). Each system’s disinfection agent and its mechanism of action require specific preparations to achieve optimal results. A room’s size and shape, the layout of its equipment and fixtures, and the reflectivity of its surfaces can all impact effectiveness.
UVC light systems need clear lines of sight to treat surfaces; if the light doesn’t hit a particular spot, it doesn’t disinfect it. That means you might have to reposition the unit between multiple cycles and move equipment around the room to ensure all surfaces are treated.
Systems that use hydrogen peroxide and other combinations of mists and vapors are less dependent on line of sight. They are, however, potentially more labor intensive because you have to cover air vents and seal OR doors before activating the devices. Time also is needed for chemicals to sufficiently dissipate before you can re-enter a disinfected room.
Hypochlorous acid (HOCl) is the perfect weapon to fight germs. It hits hard against pathogens like Methicillin-Resistant Staphylococcus Aureus and Pseudomonas Aeroginosa. Yet this powerful weapon is 100 percent safe for humans, chemical free, non-toxic and all-natural.
What makes The Annihilyzer Infection Control System better than others systems?
The Annihilyzer® uses patented and patent pending RFID/NFC technology to manage the product expiration and usage information.
When a container is filled, an expiration date is assigned to the container and imprinted on the RFID tag embedded in the bottle’s label.
The system keeps track of who filled the container and when. If an expired container is presented at the Kiosk, the PCT Annihilyzer® alerts the user to empty and refill it, ensuring the quality of the product contents.
The mobile PCT Annihilyzer Electrostatic Application System (AEAS) which is housed in a rolling cart is used quickly decontaminate and disinfect large areas, difficult to reach spaces and high-touch areas that require frequent treatment.
The AEAS electrostatic sprayer head produces positively-charged droplets of the Hydrolyte® disinfectant solution using a unique embedded-induction electrode. The electrostatic charge on every droplet pulls them towards the targeted surfaces at 75 times the force of gravity. This means droplets will even move upwards, against gravity, to coat hidden surfaces and wrap around objects, resulting in complete, even coverage of the target surfaces.
Independent tests demonstrate up to 50 percent better coverage than that achieved using non-electrostatic fogger or sprayer systems.
GREEN SEAL™ CERTIFIED 110V Units can plug right into a regular outlet snd generate full-strength hypochlorus (disinfectant) and sodium hydroxide (cleaner) on site - which can be easily dispensed on-demand. solution for our clients and our communities.
Disinfecting solutions that offer an elevated level of safety for patients, healthcare professionals, and support staff to be around; while at the same time providing an effective weapon in the fight against infection.”
We certainly have a hell of a Flagship product. Now that I gave you some candy, I'm going to throw some rocks your way.
Even though we have a very competitive product and possibly the best on the market here are the challenges we have to overcome to beat the competitors.
Getting in the hospital doors had been difficult and tedious. We still face this challenge as many hospitals and healthcare facilities have long standing relationships with some of the competitors and people don’t like change.
Our smallness limits our ability to do normal business activities on a scale that a bigger and more properly funded company does such as advertising, large sales forces and financing. We may have the best solution in town however if hospitals aren’t hearing about it how can they get it. Also companies with a large salesforce are more well equipped to sell more products not because it is better but because of contact with potential buyers and to some extent salesmanship and long standing relationships. You all heard the story about Chuck the “salesman” he could sell you your shirt off your back.
The top salespeople are usually the ones with the most activity; it doesn’t guarantee you will close more deals, but if you have no activity, you won’t be closing any deals.” – Colleen Honan, Chief Sales Officer, Brainshark
Many facilities have a contract in place for Infection Control Systems and until those contracts expire they are unavailable.
Time stops for no one. This can work for us or against us. There is a greater demand for Infection Control Systems that the market can provide. In the short term we may lose market share as we may be limited by the amount of systems we can push out but as time progresses we should be able to increase production.
What does all this mean?
PCTL has a great and competitive product however they face challenges that they should overcome as time progresses. As more and more of their systems hit the marketplace word will get out from satisfied customers. The arrival of Covid 19 has forced healthcare facilities to rethink what is the best way to keep their environments safe.
The bottom line is PCTL has possibly the best and definitely the most versatile Infection Control Systems the marketplace has ever seen.
Why has PCTL expanded so much in New York?
We have a distributor there getting the word out.
Hospitals with the systems may have shared their experiences with sister hospitals.
If we can duplicate this plan in other big market areas we may reach similar results.
That sums it up and the focus was just hospitals and PCTL’s flagship product.
What about all the other products in PCTL’s arsenal?
Bring on the competition we are locked and loaded.
This is a PCTL board.
If you do post something else at least have the decency to get your facts straight.
The flights out of China did not cease until January 23, 2020 not December 31, 2019 and that was temporary at the time. It was not an order out of Washington D.C. that did it. It was Chinese authorities. The 14 day quarantine didn't start until a week later when Washington D.C. gave the order to shut down travel from China.
Great post!!!
I received my order of pure and clean last week. If they are selling it like hotcakes, PCTL numbers probably are through the roof.
I work in a court house in Connecticut. When went to limited staffing in March. We hear only cases where people are locked up and all domestic violence cases. Most staff stay in their offices and hear cases via video. The only people in the courtroom are the Judge, clerk and defendants not in custody and marshals. Our contracted cleaners basically just wipe down high touch places daily.
Will businesses disinfect/clean with HOCI?
Possible if it is not cost prohibitive. Which I don't think it is.
We Americans are reactive and not proactive.
We had every opportunity in the world to at least fight and control the spread of the Covid 19 before we actually started getting serious about it.
HOCI here and everywhere is feasible however is it necessary.
Meat plants yes.
Hospitals yes
What may happen is when there is an outbreak somewhere then disinfection may take place.
To disinfect everywhere is just not feasible.
That is why testing is important and contact tracing will be very helpful to limit any future outbreaks.
Regardless HOCI is in high demand and will be that way for awhile
The unique stability of our HOCl products is due to our specially developed electro-dialysis cell. It means our packaged products have a shelf life of 12 months, and also enables us to produce effective biocides over a very wide pH range.
This stable, safe, and environmentally friendly product is now benefiting a huge range of new customers whose disinfection needs are too small for an on-site generator.
They include vets, farmers, pet owners, care home managers, horticulturists, food producers, and many others.
https://canamscientific.com/hocl-stability/
“The greatest enemy of knowledge is not ignorance, it is the illusion of knowledge.”
? Daniel J. Boorstin
Well they are selling it now.
10 Hospitals in New York City believes it is some pretty good kool aid
If hypochlorous acid is such a powerful weapon against germs, why isn’t it more widely used? There are a couple of reasons, one being the cost to manufacturers. HOCl was very cost prohibitive until recently. Also, HOCl is stable for only a very short time before it became saltwater. Technology has corrected this problem over the years and now, HOCl can remain stable for years and it is less costly to create.
Michael Faraday founded the laws of electrolysis and it became commercially available in the 1870s.
Generating HOCl from the electro-chemical activation (ECA) of salt water was developed in the 1970s.
Early ECA technology used membranes to force saltwater into two solutions of HOCl and NaOH.
In the 1980s, single stream systems were developed that produced one solution of HOCl without byproduct.
In recent, single stream systems have been innovated to last longer and generate more stable solutions.
“Wise men profit more by fools than fools by wise men.”
? Marcus Porcius Cato
‘Deep cleaning’ doesn’t mean anything. Still, deep cleaners are in high demand
https://www.latimes.com/business/story/2020-03-20/coronavirus-deep-cleaning-companies
It’s happened at schools, stores and offices, warehouses and city halls: Someone who might be infected with the coronavirus passes through.
The building often closes. Then come the calming words: deep cleaning.
The idea is that a thorough cleaning and disinfecting could help prevent people from getting sick. The virus is spread mainly through person-to-person contact, though people can also catch it from droplets exhaled when an infected person coughs or sneezes. Those droplets can stick to surfaces, and the virus can survive for hours or days, according to health officials.
A deep clean is supposed to kill it.
The term sounds official, but it isn’t. It has no standardized definition.
One company says the right approach is using a mechanical sprayer or thermal fogger that mists disinfectant into the air, then wiping all surfaces. Another swears by taking everything out of each room, disinfecting it all and then putting it back.
Some have warned against trusting competitors who, they say, only wipe down places that get touched a lot, like doorknobs or handles, or don’t require workers to wear heavy-duty protective gear.
“Deep cleaning is really just a term they use to make the public feel warm and fuzzy,” said Erick McCallum, founder of Texas-based the Cleaning Guys, which handled ebola cleanup during a 2014 outbreak in Dallas.
Health experts say it’s enough to clean frequently with soap, alcohol or bleach-based products. “You don’t need any unusual procedures or cleaning agents,” says Dr. Timothy Brewer, professor of medicine and epidemiology at UCLA.
That hasn’t stopped the onslaught of calls for deep cleaning.
The Servpro Extreme Response Team typically handles calls related to water or fire damage repairs in California, Nevada and Arizona. Now it gets about 100 inquiries a week on coronavirus cleanings and goes on four related calls a day.
Aftermath Services, based in Illinois, generally cleans up crime scenes and biohazards. The flood of calls about coronavirus-related cleanings threatened to overwhelm it, so the company pulled people from its finance department to help answer the phones.
“It’s all hands on deck,” said Casey Decker, Aftermath’s vice president of field services.
The calls haven’t slowed even as more companies require employees to work from home.
As restaurants, bars, gyms and other businesses close their doors, some professional cleaning firms expect demand will ramp up. Buildings can be thoroughly disinfected when there are no customers or employees inside.
“It’s very possible that almost everything will end up shutting down,” said Vanessa Cabrera, director of client services at All Clean Inc. MD, which cleans commercial and industrial properties on the East Coast. “When that’s the case, then we’ll have a lot more people calling and more jobs to do.... They’re going to want a deep clean of their facility.”
Workers, at times, might wear full-face respirators, one-piece protective suits, two pairs of gloves and booties, particularly if they’re at a place that had confirmed cases of the coronavirus. Brewer, the UCLA professor, said booties and respirators aren’t necessary. A face shield or surgical mask will do.
“When you’re going in and you’re 100% encapsulated, you feel like you can go up against anything,” Decker said of wearing a protective suit.
Cabrera’s mother, Adriana Corona, a manager at All Clean Inc. MD, is often in the field with workers and said they now wear more protective gear than they would during their normal course of work. She’s also done online training on how to do deep cleanings.
She said she hasn’t been afraid of becoming infected while on jobs. “We just clean and disinfect everything,” Corona said.
Clean Harbors, a Massachusetts company that specializes in hazardous waste removal, designates three different zones for its employees when they arrive at a decontamination job.
Workers suit up in the “warm zone” before entering the “hot zone,” where decontamination occurs. After the job is done, one person who did not enter the building helps the others take off their suits back in the warm zone before they can enter the “cold zone,” or clean area.
The protective gear is put into a drum and incinerated. The respirators are rinsed with bleach, soap and water before they’re used again.
In some ways, there’s precedent for the kind of thorough disinfection that cleaning companies are now doing. Some have compared the work to sewage and mold removal or to cleanups of crime scenes and meth labs. Some even have experience with other viruses, such as MRSA or norovirus.
“We’re used to this,” said Chuck Geer, senior vice president of field services at Clean Harbors. “It’s not uncommon at any point in time for our teams to respond to something like this.”
His company, he said, helped clean up ground zero in New York after the Sept. 11, 2001, attacks; decontaminated oily boats after the Deepwater Horizon oil rig explosion in the Gulf of Mexico; and also has experience with anthrax.
In each of these cases, “you normally know exactly what you’re cleaning up,” Geer said. But with the coronavirus, “you can’t see it,” he said. “When you go into a room or a building, you have to disinfect everything.”
Art Dickerson, president of restoration firm Paul Davis Commercial, compared coronavirus cleanings to sewage or mold cleanups. Workers use the same types of disinfectants.
But these recent jobs are on “a wider scale,” he said. “We only get so many mold jobs or sewage jobs a year.”
The demand for coronavirus cleanings has shifted Aftermath’s primary business from crime-scene cleanups to “virucidal disinfection,” a term a company official acknowledged does not roll off the tongue.
Aftermath now gets about 500 to 600 calls per day nationwide, up from its usual 50 to 75 calls. Calls have been coming in from all parts of the country, though California is a hot spot, said Vikas Chopra, director of marketing.
Prices vary depending on the size of the place to be cleaned and the types of services desired. For a 800- to 1,000-square-foot building, All Clean Inc. MD charges between $800 and $1,200. Servpro charges 50 cents to $2.50 per square foot.
But it’s important not to go overboard with the cleaning.
Using antimicrobial solutions could inadvertently lead to antimicrobial resistance that can lead to super bugs, said Erica Hartmann, assistant professor of civil and environmental engineering at Northwestern University, who specializes in environmental microbiology.
“Yes, wash your hands. Yes, you can disinfect high-touch surfaces, but within reason,” she said. “We’re not aiming to sterilize everything around us.”
COMPETITION is in PCTL past, present and future
Just focusing on our flagship product, The Annihilyzer® Infection Control System, how does PCTL compare to other companies for whole room cleaning only?
Our competitors include companies that sell whole room Infection Control Systems.
There are many different products in use to disinfect hospital rooms such as UV light, hydrogen peroxide vapor, Aerosolized hydrogen peroxide, Ozone gas, cluster ion air, Mercury UV-C light and hypochlorus acid (PCTL).
Ultraviolet light breaches the cell walls of viruses, bacteria and spores to deactivate their DNA and kill them in the air and on surfaces. Two types of devices use UV-C for germicidal irradiation: continuous light systems with 1- to 2-hour cycles and xenon-based pulsed light systems with 5- to 10-minute cycles. Both require direct illumination to treat targeted surfaces.
Hydrogen peroxide vapor systems deliver a heat-generated odorless vapor, which uses oxidative processes to kill microorganisms. When the systems are in use, a room’s doors, ducts and ventilation ports must be sealed.
Aerosolized hydrogen peroxide is uniformly sprayed with a pressure-generated aerosol, which delivers a residue-free mist that is typically made up of 5% to 6% hydrogen peroxide and a very small percentage of silver.
Ozone gas has been used in conjunction with high-powered air filtration and UV light to rid surfaces and air of microbe colonization.
Cluster ion air purifiers actively seek out pathogens via electromagnetic charge. On contact, their stored energy is unleashed through the pores of cell walls, destroying bacteria from the inside out.
Mercury UV-C light devices use low-pressure mercury gas bulbs that primarily emit a strong, narrow band of the UV-C spectrum. These devices use a dose targeted for specific types of bacteria on surfaces.
Hypochlorus acid use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched in the industry to ensure proper and complete application.
Base your whole-room disinfection choice on how a system works in practice and the value you place on reducing the risk of healthcare-acquired infections (HAIs). Each system’s disinfection agent and its mechanism of action require specific preparations to achieve optimal results. A room’s size and shape, the layout of its equipment and fixtures, and the reflectivity of its surfaces can all impact effectiveness.
UVC light systems need clear lines of sight to treat surfaces; if the light doesn’t hit a particular spot, it doesn’t disinfect it. That means you might have to reposition the unit between multiple cycles and move equipment around the room to ensure all surfaces are treated.
Systems that use hydrogen peroxide and other combinations of mists and vapors are less dependent on line of sight. They are, however, potentially more labor intensive because you have to cover air vents and seal OR doors before activating the devices. Time also is needed for chemicals to sufficiently dissipate before you can re-enter a disinfected room.
Hypochlorous acid (HOCl) is the perfect weapon to fight germs. It hits hard against pathogens like Methicillin-Resistant Staphylococcus Aureus and Pseudomonas Aeroginosa. Yet this powerful weapon is 100 percent safe for humans, chemical free, non-toxic and all-natural.
What makes The Annihilyzer Infection Control System better than others systems?
1. The Annihilyzer® uses patented and patent pending RFID/NFC technology to manage the product expiration and usage information.
When a container is filled, an expiration date is assigned to the container and imprinted on the RFID tag embedded in the bottle’s label.
2. The system keeps track of who filled the container and when. If an expired container is presented at the Kiosk, the PCT Annihilyzer® alerts the user to empty and refill it, ensuring the quality of the product contents.
3. The mobile PCT Annihilyzer Electrostatic Application System (AEAS) which is housed in a rolling cart is used quickly decontaminate and disinfect large areas, difficult to reach spaces and high-touch areas that require frequent treatment.
The AEAS electrostatic sprayer head produces positively-charged droplets of the Hydrolyte® disinfectant solution using a unique embedded-induction electrode. The electrostatic charge on every droplet pulls them towards the targeted surfaces at 75 times the force of gravity. This means droplets will even move upwards, against gravity, to coat hidden surfaces and wrap around objects, resulting in complete, even coverage of the target surfaces. Independent tests demonstrate up to 50 percent better coverage than that achieved using non-electrostatic fogger or sprayer systems.
4. GREEN SEAL™ CERTIFIED 110V Units can plug right into a regular outlet snd generate full-strength hypochlorus (disinfectant) and sodium hydroxide (cleaner) on site - which can be easily dispensed on-demand. solution for our clients and our communities.
5. Disinfecting solutions that offer an elevated level of safety for patients, healthcare professionals, and support staff to be around; while at the same time providing an effective weapon in the fight against infection.”
We certainly have a hell of a Flagship product. Now that I gave you some candy, I'm going to throw some rocks your way.
Even though we have a very competitive product and possibly the best on the market here are the challenges we have to overcome to beat the competitors.
Getting in the hospital doors had been difficult and tedious. We still face this challenge as many hospitals and healthcare facilities have long standing relationships with some of the competitors and people don’t like change.
Our smallness limits our ability to do normal business activities on a scale that a bigger and more properly funded company does such as advertising, large sales forces and financing. We may have the best solution in town however if hospitals aren’t hearing about it how can they get it.
Also companies with a large salesforce are more well equipped to sell more products not because it is better but because of contact with potential buyers and to some extent salesmanship and long standing relationships. You all heard the story about Chuck the “salesman” he could sell you your shirt off your back.
“The top salespeople are usually the ones with the most activity; it doesn’t guarantee you will close more deals, but if you have no activity, you won’t be closing any deals.” – Colleen Honan, Chief Sales Officer, Brainshark
Many facilities have a contract in place for Infection Control Systems and until those contracts expire they are unavailable.
Time stops for no one. This can work for us or against us. There is a greater demand for Infection Control Systems that the market can provide. In the short term we may lose market share as we may be limited by the amount of systems we can push out but as time progresses we should be able to increase production.
What does all this mean?
PCTL has a great and competitive product however they face challenges that they should overcome as time progresses. As more and more of their systems hit the marketplace word will get out from satisfied customers. The arrival of Covid 19 has forced healthcare facilities to rethink what is the best way to keep their environments safe. The bottom line is PCTL has possibly the best and definitely the most versatile Infection Control Systems the marketplace has ever seen.
Why has PCTL expanded so much in New York?
We have a distributor there getting the word out.
Hospitals with the systems may have shared their experiences with sister hospitals.
If we can duplicate this plan in other big market areas we may reach similar results.
That sums it up and the focus was just hospitals and PCTL’s flagship product.
What about all the other products in PCTL’s arsenal?
Bring on the competition we are locked and loaded.
Hypochlorous Acid in the Fight Against COVID-19
http://www.ocusoft.com/hypochlorous-acid-in-the-fight-against-covid-19
As news of COVID-19, the worldwide pandemic associated with severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) continues to dominate the headlines well into April of 2020, eye care providers have witnessed a tremendous alteration of their practices and lifestyles. Upon recommendations from both the American Academy of Ophthalmology and the American Optometric Association, ophthalmologists and optometrists have been advised to restrict their care to urgent and emergent cases only. This has resulted in many eye care practices across the country closing entirely, not only because of fear of the virus, but because of difficulties in obtaining personal protective equipment (PPE) and lacking appropriate protocols for patient flow and disinfection. Protection against this unforgiving virus has become a paramount concern for healthcare providers and patients alike.
As a disinfectant, the CDC recommends dilute household bleach solution (5 tablespoons per gallon of water) or solutions containing at least 70% alcohol. The agency has also endorsed a litany of other common Environmental Protection Agency (EPA)-registered household disinfectants which, although not formally tested against the SARS CoV-2 pathogen, have shown efficacy against harder to kill viruses (e.g. Norovirus and Hepatitis A).1,2 If one reviews the published list, he may recognize several active ingredients that have broad antiseptic properties, including hydrogen peroxide, quaternary ammonium and thymol in addition to many alcohol and bleach derivatives. But of particular interest, especially to eye care providers, is the inclusion of hypochlorous acid.
As a disinfectant, the CDC recommends dilute household bleach solution (5 tablespoons per gallon of water) or solutions containing at least 70% alcohol. The agency has also endorsed a litany of other common Environmental Protection Agency (EPA)-registered household disinfectants which, although not formally tested against the SARS CoV-2 pathogen, have shown efficacy against harder to kill viruses (e.g. Norovirus and Hepatitis A).1,2 If one reviews the published list, he may recognize several active ingredients that have broad antiseptic properties, including hydrogen peroxide, quaternary ammonium and thymol in addition to many alcohol and bleach derivatives. But of particular interest, especially to eye care providers, is the inclusion of hypochlorous acid.
Most of us will recognize hypochlorous acid (chemical formula: HOCl) as a now widely-utilized agent for the management of blepharitis in the United States. First introduced for ophthalmic use in 2014, HOCl is a natural antibacterial agent that is produced during the human immune response as white blood cells target pathogens within the body.3,4 This simple chemical compound has a broad spectrum of activity and exhibits rapid kill kinetics against a wide range of bacterial and viral organisms.5 Despite their efficacy however, ophthalmic formulations of HOCl are safe and extremely well-tolerated by patients.
Some of the earliest information regarding HOCl being used to contain the spread of COVID-19 came in the form of reports from South Korea. On March 3, 2020, a story by CNN about workers at drive-through corona testing stations reported that “When their shifts ends, they step fully clothed into a small portable booth called the ‘Clean Zone,’ in which they are showered in hypochlorous acid disinfectant.”6
In reviewing the EPA’s listing,2 HOCl appears a total of six times in unique products; these include such names as Cousteau (Reckitt Benckiser; Parsippany, NJ), Excelyte VET (Paradigm Convergence Technologies; Little River, SC), Danolyte (Danolyte Global; Overland Park, KS) and Cleansmart (Simple Science Limited; Edina, MN). The amount of HOCl in each of these products varies, with some as high as 500 parts per million (0.05%), but both Cousteau and Cleansmart weigh in at 0.017%. If we compare this concentration with that of known ophthalmic products containing HOCl, HypoChlor (OCuSOFT; Rosenberg, TX) meets and exceeds this percentage in that it contains 0.02% HOCl.
Charlotte Fox
Innovation Manager
Innovations
Charlotte Fox has recently joined the AHSN NENC as Innovation Manager. Prior to working in the NHS Charlotte gained a degree in Biomedical Sciences and MSc in Drug Discovery and Development and was a postgraduate oncology research assistant at the University of Sunderland with a specific interest in proteomics and genomics.
Charlotte started out her career by working as a Clinical Trials Officer, facilitating clinical trials across several specialities at Sunderland Royal Hospital. Since this time Charlotte has managed innovation across City Hospitals Sunderland NHS Foundation Trust and South Tyneside NHS Foundation Trust, working with the Research & Innovation department to develop the infrastructure to facilitate bright ideas from staff which could be developed collaboratively with regional SMEs and Universities.
Whilst working for City Hospitals Sunderland NHS Foundation Trust, Charlotte was involved in the winning entry in the 2017 Innovative Device category of the Bright Ideas in Health Awards and has had several ideas shortlisted.
Charlotte is a member of the Q community which works together to improve health and social care quality across the UK and leads a regional community of practice for innovation in healthcare.
Great to see the THE ANNIHILYZER® INFECTION CONTROL SYSTEM today
Listed as one of the top infection control innovations of 2019
This is the first site in the UK to test the system out! Supported by
Great to see the THE ANNIHILYZER® INFECTION CONTROL SYSTEM today @NTeesHpoolNHSFT
— Charlotte Fox 💚 (@CharlotteFoxNHS) March 10, 2020
Listed as one of the top infection control innovations of 2019 https://t.co/soc82uWal2
This is the first site in the UK to test the system out! Supported by @AHSN_NENC watch this space! pic.twitter.com/Jy8sF20vCi
PCTL can now be traded on TD Ameritrade Official | $0.00 Commission Online Trades?
When did this start?
Based on your opinion or understanding PCTL didnot qualify for Covid 19 Sec extension and they already used it twice.
The SEC order is basically a blanket order to get an extension to file certain documents.
Companies just have to follow the SEC requirements to get the extension which PCTL did.
PCTL has moved from toxic financing to a company on a cash flow basis to cover burn-rate.
“Patience is the calm acceptance that things can happen in a different order than the one you have in your mind.” David G. Allen
The information that will be reflective on the 10k is mostly already known from what was reported on the last quarterly dated 4/13/2020 minus companies operations for the 4th quarter. The 2020 1st quarter report should show the company transitioning as a company on a cash flow basis to cover the burn-rate. The 2nd quarter report should show significant cash flow and an explosive growth not only for fluid sales but Annihilyzers systems as well. If all what PCTL management have been reporting in recent months is true and I don’t doubt them, then the company is in a great position to grow, become financially stable and prepare themselves to move to another exchange.
The day to day stock price is just the market makers doing their job and the stock price will move up and down based on the results (fundamentals) of the company. When the results are fully realized in future reports especially starting with the 2nd quarter report then it will be reflected in the stock price. Also Press releases, podcasts, and other media outlets may influence the stock price movement.
“I’ve been called Mr. Patient Money because I have the patience to work through challenging circumstances.” – N. Murray Edwards
PCTL 4th quarter events:
PCT LTD Issues Company Update and Announcement of Collaborative Agreement for Oil & Gas and Cannabis Applications
PCT LTD Deploys Initial Annihilyzer® Infection Control System to the United Kingdom
PCT LTD Continues to Expand by Signing Long-Term Agreement with ACE
PCT LTD Announces Additional Hospital Installation of Annihilyzer® Infection Control System
From the 3rd quarter 10Q:
Common Stock
On January 28, 2019, the Company agreed to convert $131,327 of principal and interest of the notes payable described in Note 6(a) into 987,421 shares of the Company’s common stock.
On March 25, 2019, the Company issued 200,000 shares of common stock to two employees of the Company as compensation in lieu of commission on sales of the Company’s products. The Company recorded the fair value of the common shares of $34,000 in consulting expense.
On March 29, 2019, the Company executed a settlement agreement with a contractual consultant, UCAP Partners, LLC for the settlement of $25,000 owed to the contractor for the provision of services as related to the March 15, 2018 agreement between UCAP and us. The settlement terms include acknowledgement that the Company owes UCAP $25,000 as payment for said services; that UCAP purchased and fully paid for Series A Preferred Stock and Warrants from the Company on December 3, 2018 (100,000 Preferred Series A Shares and 100,000 warrants to purchase common shares at $0.10/share); the settlement is outlined as follows: the Company shall issue 164,000 shares of its common stock as payment in full for the services rendered on the consulting contract; the Company shall accept UCAP’s conversion and exercise of the purchased 100,000 Preferred Series A shares into 100,000 shares of the Company’s common stock and the Company shall accept the cashless conversion of UCAP’s 100,000 warrant into 34,400 shares of the Company’s restricted common stock; and, as inducement for and consideration for the settlement of the Company’s debt to UCAP, the Company agrees to grant 500,000 additional shares of the Company’s restricted stock. As a result During the nine months ended September 30, 2019, the Company issued a total of 4,999,000 shares of the Company’s common stock upon the conversion of $2,196 of principal and $953 of interest pursuant to the convertible note payable described in Note 6(o).
During the nine months ended September 30, 2019, the Company issued a total of 5,555,555 shares of the Company’s common stock upon the conversion of $5,000 of principal pursuant to the convertible note payable described in Note 6(p).
of this transaction, 3,597,989 shares of Company’s common stock were issued and a $55,830 loss on settlement of debt was recognized.
During the nine months ended September 30, 2019, the Company issued a total of 76,154,631 shares of the Company’s common stock upon the conversion of $44,723 of principal ($42,223) and interest ($2,500) pursuant to the convertible note payable described in Note 6(i).
During the nine months ended September 30, 2019, the Company issued a total of 66,290,000 shares of the Company’s common stock upon the conversion of $64,558 of principal ($58,058) and interest ($6,500) pursuant to the convertible note payable described in Note 6(j).
During the nine months ended September 30, 2019, the Company issued a total of 18,559,816 shares of the Company’s common stock upon the conversion of $74,200 of the convertible note payable pursuant to the convertible note payable described in Note 6(k).
During the nine months ended September 30, 2019, the Company issued a total of 5,207,600 shares of the Company’s common stock upon the conversion of $4,508 of the convertible note payable and $179 of accrued interest pursuant to the convertible note payable described in Note 6(m).
During the nine months ended September 30, 2019, the Company issued a total of 7,500,000 shares of the Company’s common stock upon the conversion of $8,640 of principal pursuant to the convertible note payable described in Note 6(n).
During the nine months ended September 30, 2019, the Company issued a total of 3,054,511 shares of the Company’s common stock upon the conversion of $13,000 of principal pursuant to the convertible note payable described in Note 6(q).
During the nine months ended September 30, 2019, the Company issued a total of 11,490,000 shares of the Company’s common stock upon the conversion of $27,804 of the convertible note payable and $5,287 of accrued interest pursuant to the convertible note payable described in Note 6(s).
On August 16, 2019, the Company issued 5,989,500 shares of common stock upon the cashless exercise of 6,000,000 warrants.
On September 24, 2019, the Company issued 6,041,381 shares of common stock upon the cashless exercise of 6,057,143 warrants.
On August 1, 2019, the Company entered into a consulting agreement for investor relations services through September 30, 2019. The agreement called for 1,000,000 restricted shares of common stock to be issued to the consultant. As of September 30, 2019, the Company recorded $15,000 in additional paid-in capital for the consulting expense related to the consulting services provided, due to the fact that the 1,000,000 common shares were issued subsequently on March 11, 2020.
NOTE 10 – WARRANTS
As described in Note 6, from February 14 through September 11, 2019, the Company issued 487,500 warrants subject to an exercise price of $0.20 per share for 5 years and 300,000 warrants subject to an exercise price of $0.10 per share for 5 years. If the Company issues any common stock or common stock equivalents at an effective price per share less than the warrant’s exercise price the exercise price of the warrants will be reduced to the lower price. In addition, the number of common shares issuable upon conversion of the warrants is increased so that the number of shares issuable multiplied by the exercise price equals the aggregate exercise price of the warrants immediately prior to the exercise reduction. During period, convertible notes were exercised at a price less than the original exercise price of these warrants, resulting in an adjustment to the number of warrants and exercise price.
NOTE 13. SUBSEQUENT EVENTS
On October 1, 2019, the Company entered into a consulting agreement for investor relations services through March 31, 2020. The agreement called for a cash payment of $25,000 and 12,000,000 restricted shares of common stock to be issued to the consultant. The Company issued the 12,000,000 common shares to the consultant on March 16, 2020.
On October 3, 2019, the Company entered into a promissory note with a non-related party for $50,000. The note is due on April 3, 2020 and bears interest at a rate of 12%. On October 9, 2020, the Company had repaid $12,599 of the loan. On March 8, 2020, the Company agreed to settle the remaining $39,054 of principal and accrued interest outstanding on the note through the issuance of 39,000 Shares of Series A Preferred Stock and the payment of $54.
On October 4, 2019, F. Jody Read stepped down from his position as Chief Executive Officer of the Registrant due to increased workload in the Registrant’s wholly-owned operating subsidiary. Mr. Read remains as a director and Chief Operating Officer of the Registrant. Concurrent with Mr. Read stepping down from the position of Chief Executive Officer, the Registrant appointed Mr. Gary J. Grieco to act as President and Chief Executive Officer of the Registrant.
On October 7, 2019, the Company entered into a convertible promissory with a non-related party for $53,000 of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $50,000. The note is due on October 7, 2020 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note’s term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date.
On October 8, 2019, the Company issued 6,399,302 shares of common stock upon the cashless exercise of 6,424,286 warrants.
On October 22, 2019, the Company issued 6,498,105 shares of common stock upon the cashless exercise of 6,528,571 warrants.
On October 29, 2019, the Company entered into a convertible promissory with a non-related party for $50,000 of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $47,000. The note is due on October 29, 2020 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note’s term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date.
On November 12, 2019, the Company entered into a promissory note with a non-related party for $17,500. The note is due November 12, 2020, is unsecured and bears an interest rate of 8% per annum.
On December 12, 2019, the Company entered into a loan with a non-related party for $12,250 of which $2,250 was the loan fee or original issue discount resulting in cash proceeds to the Company of $10,000. The note is to be repaid through 12 monthly payments ending on May 12, 2020.
On December 19, 2019, the Company sold future receivables of $83,400 in consideration for $58,200. The advance is to be repaid through $3,208 weekly payments. In connection with the advance, the Company granted the lender a security interest in all accounts, equipment, intangibles and inventory.
On December 20, 2019, the Company sold future receivables of $148,362 in consideration for $100,000. The advance is to be repaid through $2,958 weekly payments.
On December 31, 2019, the Company sold future receivables of $87,540 in consideration for $60,000. The advance is to be repaid through $3,651 weekly payments. The Company paid $3,625 of finance fees and includes default fees of up to $2,500 and a default rate of interest of 9%. In connection with the advance, the Company granted the lender a security interest in all accounts, equipment, intangibles and inventory. As of the date of filing the Company had only received advances of $15,575.
From October 1, 2019 through March 25, 2020, the Company issued a total of 265,453,351 shares of common stock upon the conversion of $286,043 of principal, $20,306 of interest and of fees pursuant to the convertible notes payable described in Note 6.
Liquidity and Capital Resources
A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate generating sufficient positive internal operating cash flow until such time as we can deliver our products to market and generate substantial revenues, which may take the next full year to fully realize, if ever. In the event we cannot obtain the necessary capital to pursue our strategic plan, we may have to significantly curtail our operations. This would materially impact our ability to continue operations.
At September 30, 2019, the Company recorded a net loss for the nine month period of $10,214,462 and had a working capital deficit of $8,934,741. We have recorded revenues from operations, but these have been insufficient to cover our operating costs. During the nine months ended 2019 and 2018 we have primarily relied upon advances and loans from stockholders and third parties to fund our operations. The Company has relied on raising debt and equity capital in order to fund its ongoing day-to-day operations and its corporate overhead. We had $6,669 in cash at September 30, 2019, compared to $4,893 in cash at December 31, 2018. We had total liabilities of $9,097,175 at September 30, 2019 compared to $3,141,401 at December 31, 2018.
Our current cash flow is not sufficient to meet our monthly expenses of approximately $210,000 and to fund future research and development. We intend to rely on additional debt financing, loans from existing stockholders and private placements of our securities for additional funding in addition to the increasing our recognized revenue from the leasing and/or sale of products; however, there is no assurance that additional funding will be available. We do not have material commitments for future capital expenditures. However, we cannot assure you that we will be able to obtain short-term financing, or that sources of such financing, if any, will continue to be available, and if available, that they will be on favorable terms.
PCTL
1. If it were to merge it probably would be the easiest as it would most likely be an industry peer so it would be an easy sell as the already know the business and just need to look at some numbers.
2. Deep Pocket Investor probably would be the hardest especially if they don't know the technology or have trusted friends that could bring them up to speed. Heck look what it took to get into hospitals.
3. Last and not least is a buyout.
Why do companies buyout other companies or ideas?
Greed
In the seventies cars companies bought out inventors ideas.
How much would PCTL be worth?
Out of the three the most likely is a Deep Pocket Investor.
PCTL management has too much invested, worked many years,overcame insurmountable hurdles to get the Annihilyzer in the marketplace.
I cannot fathom PCTL letting any filing be late without filing the proper paperwork as they did today.
They have viable products they are selling like hotcakes and one of which (Infection Control Systems) their industry peers are saying they can't keep up with demand.
My gut tells me PCTL is up to something that is very beneficial to the company.
It could be a Deep Pocket Investor.
It could be a merger.
It could be a buyout.
The ball is definitely in PCTL court and how they handle it hopefully will be masterful.
What is intriguing is the cash flow and the need for at least 25 systems a month starting in July which is about 45 days away.
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow is the being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
I think they are going to need some serious cash to build at minimum 25 systems a month.
I think people truly understands what a viable position PCTL and similar companies are in with arrival of the Pandemic and the tools these companies have to combat it.
Happy Trading and stay safe during your flight duties.
There are many companies that filed a NT 10-k today.
Items 1 - 40 Latest Filings RSS Feed
Form Formats Description Accepted Filing Date File/Film No
BRIDGEWAY NATIONAL CORP. (0001567771) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008840 Act: 34 Size: 27 KB 2020-05-14
17:20:16 2020-05-14 000-55505
20879033
Muscle Maker, Inc. (0001701756) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008828 Act: 34 Size: 28 KB 2020-05-14
17:15:15 2020-05-14 001-39223
20878964
FTE Networks, Inc. (0001122063) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008818 Act: 34 Size: 38 KB 2020-05-14
17:10:02 2020-05-14 001-38322
20878856
Golden Developing Solutions, Inc. (0001736865) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008810 Act: 34 Size: 43 KB 2020-05-14
17:06:39 2020-05-14 000-56051
20878819
Alternus Energy Inc. (0001621499) (Filer)
NT 10-K/A [html][text] [Amend] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001477932-20-002682 Act: 34 Size: 19 KB 2020-05-14
17:04:46 2020-05-14 000-56085
20878788
Rocky Mountain High Brands, Inc. (0001670869) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001663577-20-000145 Act: 34 Size: 16 KB 2020-05-14
16:56:07 2020-05-14 000-55609
20878634
Cool Holdings, Inc. (0001274032) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001564590-20-025502 Act: 34 Size: 40 KB 2020-05-14
16:55:51 2020-05-14 001-32217
20878631
Driven Deliveries, Inc. (0001629606) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012312 Act: 34 Size: 19 KB 2020-05-14
16:53:49 2020-05-14 333-209836
20878602
PCT LTD (0001119897) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001554795-20-000131 Act: 34 Size: 24 KB 2020-05-14
16:53:32 2020-05-14 000-31549
20878595
FRESH PROMISE FOODS, INC. (0001058330) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001721868-20-000225 Act: 34 Size: 16 KB 2020-05-14
16:45:18 2020-05-14 000-24723
20878493
Rennova Health, Inc. (0000931059) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008782 Act: 34 Size: 49 KB 2020-05-14
16:42:52 2020-05-14 001-35141
20878465
GSE SYSTEMS INC (0000944480) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0000944480-20-000029 Act: 34 Size: 15 KB 2020-05-14
16:42:03 2020-05-14 001-14785
20878458
Intelligent Buying, Inc. (0001358633) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001731122-20-000499 Act: 34 Size: 20 KB 2020-05-14
16:35:42 2020-05-14 001-34861
20878384
RumbleON, Inc. (0001596961) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001654954-20-005492 Act: 34 Size: 67 KB 2020-05-14
16:30:40 2020-05-14 001-38248
20878264
Umatrin Holding Ltd (0001317839) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001477932-20-002672 Act: 34 Size: 21 KB 2020-05-14
16:30:38 2020-05-14 000-51190
20878263
CANCER GENETICS, INC (0001349929) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008768 Act: 34 Size: 38 KB 2020-05-14
16:30:33 2020-05-14 001-35817
20878257
Crypto Co (0001688126) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008765 Act: 34 Size: 36 KB 2020-05-14
16:30:24 2020-05-14 000-55726
20878247
ChinaNet Online Holdings, Inc. (0001376321) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001171843-20-003724 Act: 34 Size: 26 KB 2020-05-14
16:30:11 2020-05-14 001-34647
20878239
ComSovereign Holding Corp. (0001178727) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012290 Act: 34 Size: 23 KB 2020-05-14
16:28:44 2020-05-14 333-150332
20878219
REGO PAYMENT ARCHITECTURES, INC. (0001437283) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001214659-20-004571 Act: 34 Size: 25 KB 2020-05-14
16:15:27 2020-05-14 000-53944
20877949
Future FinTech Group Inc. (0001066923) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012273 Act: 34 Size: 19 KB 2020-05-14
16:15:21 2020-05-14 001-34502
20877945
MassRoots, Inc. (0001589149) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012272 Act: 34 Size: 26 KB 2020-05-14
16:15:18 2020-05-14 000-55431
20877943
TARONIS TECHNOLOGIES, INC. (0001353487) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008741 Act: 34 Size: 40 KB 2020-05-14
16:05:26 2020-05-14 001-35586
20877713
Kisses From Italy, Inc. (0001608092) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001683168-20-001562 Act: 34 Size: 24 KB 2020-05-14
16:00:40 2020-05-14 000-55967
20877612
United Health Products, Inc. (0001096938) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001477932-20-002665 Act: 34 Size: 18 KB 2020-05-14
16:00:12 2020-05-14 000-27781
20877595
FISION Corp (0001487931) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001477932-20-002664 Act: 34 Size: 18 KB 2020-05-14
15:57:16 2020-05-14 000-53929
20877583
INTERNET SCIENCES INC. (0001720286) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001721868-20-000222 Act: 34 Size: 27 KB 2020-05-14
15:52:52 2020-05-14 000-55897
20877562
Digital Development Partners, Inc. (0001409999) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001104659-20-061559 Act: 34 Size: 26 KB 2020-05-14
15:45:42 2020-05-14 000-52828
20877538
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (0001697805) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012234 Act: 34 Size: 36 KB 2020-05-14
15:34:48 2020-05-14 001-38120
20877486
Dream Homes & Development Corp. (0001518336) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008727 Act: 34 Size: 29 KB 2020-05-14
15:33:05 2020-05-14 000-55445
20877381
VNUE, Inc. (0001376804) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001477932-20-002659 Act: 34 Size: 19 KB 2020-05-14
15:30:49 2020-05-14 000-53462
20877372
ORIGINCLEAR, INC. (0001419793) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012229 Act: 34 Size: 20 KB 2020-05-14
15:30:36 2020-05-14 333-147980
20877371
AMERICAN EDUCATION CENTER, INC. (0001626556) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001104659-20-061543 Act: 34 Size: 20 KB 2020-05-14
15:28:38 2020-05-14 333-201029
20877365
Jade Global Holdings, Inc. (0001518171) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012222 Act: 34 Size: 28 KB 2020-05-14
15:25:46 2020-05-14 000-54828
20877351
MESO NUMISMATICS, INC. (0001760026) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001213900-20-012210 Act: 34 Size: 32 KB 2020-05-14
15:10:55 2020-05-14 000-56010
20877283
High Sierra Technologies, Inc. (0001365388) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001548123-20-000057 Act: 34 Size: 11 KB 2020-05-14
14:49:32 2020-05-14 000-52036
20877116
KIWA BIO-TECH PRODUCTS GROUP CORP (0001159275) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008699 Act: 34 Size: 26 KB 2020-05-14
14:42:52 2020-05-14 000-33167
20877081
Exactus, Inc. (0001552189) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001415889-20-001179 Act: 34 Size: 19 KB 2020-05-14
14:26:17 2020-05-14 001-38190
20877012
DIEGO PELLICER WORLDWIDE, INC (0001559172) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001731122-20-000496 Act: 34 Size: 21 KB 2020-05-14
14:22:14 2020-05-14 000-55815
20876967
Clean Energy Technologies, Inc. (0001329606) (Filer)
NT 10-K [html][text] Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Accession Number: 0001493152-20-008687 Act: 34 Size: 28 KB
8K
Accordingly, the Registrant has decided to rely on the SEC Order and endeavor to file the Quarterly Report no later than June 29, 2020, or within 45 days after the original due date. The reason the Form 10-Q cannot be filed timely does not relate to the inability of any person, other than the Registrant, to furnish any required opinion, report, or certification.
https://www.sec.gov/Archives/edgar/data/1119897/000155479520000133/pctl0514form8k.htm
Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
https://www.sec.gov/cgi-bin/browse-edgar?company=pct+ltd&owner=exclude&action=getcompany
I said the 1OK is going to be terrible. I never said anything specifically about the 1st quarter 10Q but I will now.
It will show promise but it will also show some of the converted debt.
The 2nd quarter 10Q is where the BIG BOOM will come.
Some of or part of the shares from the following information will be in the 10K and the 1st quarter 10Q:
From October 1, 2019 through March 25, 2020, the Company issued a total of 265,453,351 shares of common stock upon the conversion of $286,043 of principal, $20,306 of interest and of fees pursuant to the convertible notes payable described in Note 6.
The 10K is not going to be great as a matter of fact it is going to be down right terrible.
Not to worry though the the financials to follow will show so promise of greatness before the BIG BOOM !!!
“We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, delivering at least 25 systems a month,” said Grieco.
PCTL business progression did not happen overnight nor over a few events but over many months, hurdles, frustrations and struggles.
Financial difficulties and trying to establish a foothold in the Infection Control industry just to name a few.
If PCTL takes care of business than the stock price will respond accordingly in the weeks, months and years to come.
Various Technological Advancements are set to Grow the Global Biotechnology Market
https://www.biospace.com/article/releases/various-technological-advancements-are-set-to-grow-the-global-biotechnology-market/
PCTL has made tremendous progess from significant a company milestone reached just 18 months ago (November 2018):
The company announced that they have, "reached significant company milestones through its wholly-owned operating subsidiary Paradigm Convergence Technologies Corporation (PCT Corp.). PCT Corp. has successfully completed two Beta Site trials and installations at major healthcare facilities, which have been converted into long-term agreements for its Annihilyzer® Infection Control Systems. PCT Corp. has also established agreements with several Manufacturing Representatives for geographical territories in the healthcare market. With these milestones achieved, PCT Corp. has commenced the full-scale marketing launch of its hospital infection control systems.
PCTL has seen the an explosive growth in sales and services in the last quarter and has deployed Annihilyzer Infection Control Systems in at least 13 hospitals and have expanded operations to at least 15 states/countries.
“We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, delivering at least 25 systems a month,” said Grieco.
We had to turn down business in a "Major Market" due to the Pandemic Crisis:
Grieco then addressed rumors that the Company is expanding into China. Grieco shared that the Company signed an MOU in January of 2020, which required the Company to deliver systems. “When the pandemic broke, we took that out of the equation,” said Grieco. “What we have done is tabled any discussions until late summer,” he continued. “I don’t feel that we should be shipping any systems anywhere as long as we need them here in the United States.”